US Bancorp DE Sells 816 Shares of Azenta, Inc. $AZTA

US Bancorp DE lessened its holdings in shares of Azenta, Inc. (NASDAQ:AZTA) by 18.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,565 shares of the company’s stock after selling 816 shares during the quarter. US Bancorp DE’s holdings in Azenta were worth $123,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its position in shares of Azenta by 195.3% in the fourth quarter. Russell Investments Group Ltd. now owns 12,904 shares of the company’s stock valued at $645,000 after purchasing an additional 8,534 shares during the period. Bank of Montreal Can raised its position in shares of Azenta by 17.4% in the fourth quarter. Bank of Montreal Can now owns 9,097 shares of the company’s stock valued at $455,000 after purchasing an additional 1,350 shares during the period. Invesco Ltd. raised its position in shares of Azenta by 39.3% in the fourth quarter. Invesco Ltd. now owns 218,795 shares of the company’s stock valued at $10,940,000 after purchasing an additional 61,678 shares during the period. Raymond James Financial Inc. bought a new position in shares of Azenta in the fourth quarter valued at approximately $2,331,000. Finally, Sterling Capital Management LLC raised its position in shares of Azenta by 39.8% in the fourth quarter. Sterling Capital Management LLC now owns 2,856 shares of the company’s stock valued at $143,000 after purchasing an additional 813 shares during the period. Institutional investors own 99.08% of the company’s stock.

Azenta Stock Performance

Shares of NASDAQ AZTA opened at $30.39 on Monday. The stock has a market cap of $1.39 billion, a PE ratio of -12.56 and a beta of 1.59. The business has a fifty day moving average of $31.31 and a two-hundred day moving average of $33.36. Azenta, Inc. has a 52-week low of $23.91 and a 52-week high of $55.63.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Azenta had a positive return on equity of 1.35% and a negative net margin of 18.45%. The company had revenue of $143.94 million during the quarter, compared to analysts’ expectations of $149.64 million. During the same period last year, the business earned $0.14 earnings per share. The business’s revenue was up .0% on a year-over-year basis. Analysts predict that Azenta, Inc. will post 0.53 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Evercore ISI set a $33.00 price objective on shares of Azenta and gave the stock an “in-line” rating in a research note on Tuesday, August 5th. Needham & Company LLC lowered their price objective on shares of Azenta from $59.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Raymond James Financial upgraded shares of Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 price objective on the stock in a research note on Wednesday, August 6th. Finally, Stephens assumed coverage on shares of Azenta in a research note on Tuesday, July 22nd. They issued an “equal weight” rating and a $35.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $35.75.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.